Cargando…

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial

Detalles Bibliográficos
Autores principales:	De Angelis, Claudia, Ignatiadis, Michail, Piccart-Gebhart, Martine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723614/ https://www.ncbi.nlm.nih.gov/pubmed/33313083 http://dx.doi.org/10.21037/atm-20-3216

Ejemplares similares

Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression
por: Foldi, Julia, et al.
Publicado: (2023)

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
por: Johnston, Stephen, et al.
Publicado: (2023)

Efficient Wnt mediated intestinal hyperproliferation requires the cyclin D2-CDK4/6 complex
por: Myant, Kevin, et al.
Publicado: (2011)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
por: Li, Zhen, et al.
Publicado: (2020)

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
por: Finn, Richard S., et al.
Publicado: (2016)

Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
por: Thill, Marc, et al.
Publicado: (2018)

Lineage specific composition of cyclin D–CDK4/CDK6–p27 complexes reveals distinct functions of CDK4, CDK6 and individual D‐type cyclins in differentiating cells of embryonic origin
por: Bryja, V., et al.
Publicado: (2008)

The Role of Cyclin-Dependent Kinases (CDK) 4/6 in the Ovarian Tissue and the Possible Effects of Their Exogenous Inhibition
por: Scavone, Graziana, et al.
Publicado: (2023)

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
por: Yıldırım, Hasan Çağrı, et al.
Publicado: (2022)

CDK4/6 and diffuse intrinsic pontine glioma - Evaluate at diagnosis?
por: Becher, Oren J.
Publicado: (2019)

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
por: Kang, Jian, et al.
Publicado: (2014)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma
por: Matsumoto, M, et al.
Publicado: (1999)

A novel role for the cell cycle regulatory complex cyclin D1–CDK4 in gluconeogenesis
por: Hosooka, Tetsuya, et al.
Publicado: (2015)

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2021)

Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma
por: Chen, Dehong, et al.
Publicado: (2020)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Pack, Lindsey R., et al.
Publicado: (2021)

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
por: Ogata, Ryohei, et al.
Publicado: (2020)

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2022)

Oxygen-independent, CDK4/CDK6-dependent degradation of hypoxia-inducible factor-1α takes cancers’ breath away
por: Neckers, Len
Publicado: (2022)

CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
por: Nardone, Valerio, et al.
Publicado: (2021)

Cyclin-dependent kinase 6 (CDK6) as a potent regulator of the ovarian primordial-to-primary follicle transition
por: Ataei-Nazari, S., et al.
Publicado: (2022)

Cyclin-dependent kinase 4/6 inhibition in cancer therapy
por: Johnson, Neil, et al.
Publicado: (2012)

Molecular docking analysis of piperine with CDK2,CDK4,Cyclin D and Cyclin T proteins
por: Rekha, Umapathy Vidhya, et al.
Publicado: (2020)

Cyclin D/CDK4/6 activity controls G1 length in mammalian cells
por: Dong, Peng, et al.
Publicado: (2018)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

APC/C prevents non-canonical order of cyclin/CDK activity to maintain CDK4/6 inhibitor-induced arrest
por: Mouery, Brandon L, et al.
Publicado: (2023)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
por: Raspé, Eric, et al.
Publicado: (2017)

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines
por: Coxon, Christopher R., et al.
Publicado: (2016)

Temporal changes in cyclinD-CDK4/CDK6 and cyclinE-CDK2 pathways: implications for the mechanism of deficient decidualization in an immune-based mouse model of unexplained recurrent spontaneous abortion
por: Chang, Zhuo, et al.
Publicado: (2022)

Are all cyclin-dependent kinases 4/6 inhibitors created equal?
por: Marra, Antonio, et al.
Publicado: (2019)

The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
por: Tanaka, Tomohito, et al.
Publicado: (2017)

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
por: Bisi, John E., et al.
Publicado: (2017)

Cdk2 and Cdk4 cooperatively control the expression of Cdc2
por: Berthet, Cyril, et al.
Publicado: (2006)

CDK4/6 inhibition protects normal cells against cancer therapy-induced damage
por: Boopathi, Ettickan, et al.
Publicado: (2020)

Cyclin-dependent kinase 6 (CDK6) is a candidate diagnostic biomarker for early non-small cell lung cancer
por: Gong, Wangang, et al.
Publicado: (2020)

Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
por: Liu, Jingyi, et al.
Publicado: (2018)

Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer
por: Gomes, Inês, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kgjbt69vs4ln0rspm8trgd15oi